Can MK-677 raise blood sugar or affect insulin sensitivity?

MK-677 can transiently raise fasting blood glucose and reduce insulin sensitivity in some users, particularly at higher doses. This is a known effect of sustained GH elevation: growth hormone is counter-regulatory to insulin. People with pre-diabetes, diabetes, or metabolic syndrome should have this evaluated carefully before considering MK-677.

Athlete preparing to deadlift a barbell, representing the strength and recovery goals associated with MK-677

MK-677 Side Effects: Your Top Questions Answered

Q: What are the most common MK-677 side effects?

The most commonly reported MK-677 side effects are water retention (edema), increased appetite, and transient fatigue or lethargy — particularly in the early weeks of use. These effects are mechanistically linked to MK-677's ghrelin-mimicking activity and the resulting rise in growth hormone and IGF-1 levels.

Q: Does MK-677 cause water retention?

Yes. Water retention is the most consistently reported side effect of MK-677. Elevated GH and IGF-1 promote sodium and water reabsorption by the kidneys, which can cause noticeable puffiness in the hands, face, and lower extremities — particularly at higher doses. This typically improves as the body adjusts or when the dose is reduced.

Q: Does MK-677 affect cortisol or prolactin?

Some studies have observed modest increases in cortisol and prolactin with MK-677 use, consistent with its ghrelin receptor activity. These elevations are generally small and transient, but they are worth monitoring — especially for anyone with thyroid conditions, pituitary history, or concerns about cortisol-related symptoms.

Q: Is MK-677 safe for long-term use?

Long-term safety data for MK-677 in healthy adults remains limited. The longest published studies ran approximately two years and showed sustained GH and IGF-1 elevation with acceptable tolerability in selected populations. However, the sustained elevation of IGF-1 over years raises theoretical concerns — including effects on cell proliferation — that have not been fully characterized in long-duration human trials.

Q: Who should avoid MK-677?

MK-677 is generally not appropriate for people with active cancer or a history of hormone-sensitive cancers (given the IGF-1 elevation), those with poorly controlled diabetes or insulin resistance, individuals with significant edema-related conditions such as heart failure, and those currently taking medications that interact with GH or insulin pathways. A licensed provider evaluation is essential before use.

Q: Is MK-677 FDA-approved?

No. MK-677 is not FDA-approved for any indication in the United States. It has been studied in clinical trials for conditions including growth hormone deficiency, sarcopenia, and hip fracture recovery, but has not completed the approval process. Compounded MK-677 available through telehealth platforms is not FDA-approved.

MK-677 (ibutamoren) raises growth hormone and IGF-1 by mimicking ghrelin, but its side effect profile deserves careful attention before starting. This Q&A covers what the evidence shows — MK-677 is not FDA-approved for human use — and what to discuss with a provider at TelosRX.

MK-677 is an oral growth hormone secretagogue with a well-studied mechanism and a growing user base in performance, recovery, and anti-aging contexts. Unlike injectable peptides, it activates GH release through the ghrelin receptor without requiring needles or refrigeration. But “well-studied mechanism” does not mean “without tradeoffs.” Below are the most common questions people ask before starting.

Q: What are the most common MK-677 side effects?

The most consistently reported side effects of MK-677 are:

Water retention (edema) — the most common, particularly in hands, face, and lower extremities
Increased appetite — expected from ghrelin receptor activation; can be significant
Transient lethargy or fatigue — most pronounced in early weeks as GH levels adjust
Vivid dreams or altered sleep architecture — GH is primarily released during slow-wave sleep; MK-677 amplifies this, which some users find disruptive

These effects are dose-dependent: lower doses (10–15 mg nightly) typically produce milder side effects than higher ranges (25 mg+).

Q: Why does MK-677 cause water retention?

Elevated growth hormone and IGF-1 promote sodium and water reabsorption through the kidneys — a mechanism seen with GH therapy in general. The result is puffiness that is often noticeable first in the face and fingers. For most people, this stabilizes after 2–4 weeks as the body adjusts. Reducing sodium intake and staying well-hydrated can help. If edema is significant or worsening, dose reduction or discontinuation should be discussed with a provider.

Q: Can MK-677 raise blood sugar?

Yes — this is an important consideration. Growth hormone is counter-regulatory to insulin: sustained GH elevation reduces insulin sensitivity and can raise fasting glucose in some users. Clinical studies on MK-677 have observed modest fasting glucose increases, particularly at higher doses and in individuals with existing metabolic risk factors.

People with pre-diabetes, type 2 diabetes, or significant insulin resistance should discuss this risk directly with a licensed provider before starting MK-677. Periodic glucose monitoring during use is reasonable for anyone in this category.

Q: Does MK-677 affect cortisol or prolactin?

Some clinical studies have noted mild transient increases in cortisol and prolactin with MK-677, consistent with its ghrelin receptor activity. In most published trials, these elevations were modest and not clinically significant at standard doses. However, for individuals with thyroid disorders, pituitary history, or existing elevated cortisol concerns, these potential effects are worth discussing with a provider before starting.

Q: Is MK-677 safe for long-term use?

This question does not have a fully settled answer. The longest published human trials ran approximately two years and showed sustained GH/IGF-1 elevation with generally acceptable tolerability. However, several uncertainties persist:

IGF-1 and cell proliferation — IGF-1 is a growth factor; chronically elevated levels over years carry theoretical concerns about stimulating abnormal cell growth that have not been characterized in long-duration trials
Insulin sensitivity — chronic GH elevation may progressively reduce insulin sensitivity in susceptible individuals
Cardiovascular effects — GH has complex effects on cardiac function; long-term data in healthy adults using MK-677 specifically is limited

Cautious use means starting at a lower dose, monitoring labs periodically (IGF-1, glucose, lipids), and reassessing every few months with a provider.

Considering MK-677? At TelosRX, a licensed provider reviews your health history asynchronously and determines whether MK-677 is appropriate for your situation — no live appointment required. Approval is subject to medical evaluation by a licensed provider and is not guaranteed. Submit your intake today.

Q: Who should avoid MK-677?

MK-677 is generally not appropriate for:

People with active cancer or a personal history of hormone-sensitive cancers (breast, prostate, colorectal)
Those with poorly controlled type 2 diabetes or significant insulin resistance
Individuals with conditions sensitive to fluid retention, such as congestive heart failure or severe kidney disease
Anyone taking medications that interact with GH, insulin signaling, or prolactin pathways
Pregnant or breastfeeding individuals

This is why provider evaluation before starting is not optional — it is the mechanism by which serious contraindications get caught.

Q: Is MK-677 FDA-approved?

No. MK-677 is not FDA-approved for any indication. It has been studied in clinical trials for growth hormone deficiency, sarcopenia, and hip fracture recovery, but has not completed the regulatory approval process. Compounded MK-677 available through telehealth platforms is not FDA-approved and is not equivalent to an FDA-approved drug. Using it requires careful consideration of this regulatory status and what it means for quality oversight and evidence standards.

Getting Started Responsibly

The side effect profile of MK-677 is manageable for many people when approached at appropriate doses with baseline labs and periodic monitoring. Water retention and appetite increase are the most predictable effects; blood glucose and IGF-1 changes require monitoring in anyone with metabolic risk factors.

A licensed provider reviewing your case asynchronously can identify contraindications, recommend an appropriate starting dose, and outline what labs to track. This evaluation is the minimum standard before starting any compounded peptide.

Start your private evaluation at TelosRX.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.